Kristina Saffran was just 10 years old when she was diagnosed with anorexia, launching her into years of cycling in and out of treatment as a teenager. Now she is on the other side of the treatment model, running Equip, a virtual eating disorder treatment company that has rapidly spread across the country. The startup leans on family‑based therapy delivered by multidisciplinary teams and has pushed outpatient care - and its limits - into the spotlight.
According to The San Diego Union‑Tribune, PitchBook values Equip at roughly $900 million, and the paper reports the company has treated more than 15,000 patients. It also notes that cash costs for families without coverage run about $2,500 to $4,000 per month. Equip says it was co‑founded in 2019 by Saffran and Dr. Erin Parks and that each family is assigned a five‑person care team, and the company also says most patients get coverage through insurance, according to Equip.
Evidence And Limits Of Family‑Based Treatment
Family‑based treatment (FBT), which asks family members to take an active role in renourishing and supervising recovery, is the clinical backbone of Equip’s program. A recent naturalistic study reported that about 61.5% of anorexia patients reached full weight restoration by the end of treatment, according to the Journal of Eating Disorders, while systematic reviews put full remission rates in the roughly 40 to 50% range, per a review in Frontiers. Equip layers, peer and family mentors, plus remote medical oversight onto that FBT core, a setup described as super‑charged family‑based treatment, according to Vogue. At the same time, clinicians stress that variable long‑term relapse risk means expansion needs to be matched with careful tracking of outcomes.
Payers, Funding And What To Watch
Equip says it has raised major venture backing, and the company’s leadership page notes about $110 million in total funding from investors, including F‑Prime, The Chernin Group, Tiger Global, Optum Ventures, and General Catalyst, money that has helped the startup secure payer contracts and scale nationally, according to Equip. Rapid growth has helped warm payers to virtual FBT, but experts and reporters warn that insurer ties and aggressive growth targets should not get ahead of independent outcome measurement and efforts to reach lower‑income and underrepresented patients. Observers have pointed to telehealth’s surge during the pandemic as both an opportunity and a cautionary tale, according to Wired.
Saffran’s arc, from a teen who says she “almost died” from anorexia to CEO of a high‑value health startup, highlights how survivor leadership can reshape access to care. At the same time, the clinical literature shows FBT works for many yet not all patients, so families and local clinicians will be watching closely to see whether the headlines about valuation and scale are matched by transparent, durable outcomes for the people this care is supposed to help.
